ISF 35

Drug Profile

ISF 35

Alternative Names: Ad-CD154; Ad-ISF35; Ad-ISF35 transduced CLL B-cells; Adenovirus-CD 154; Immune Stimulatory Factor 35; ISF-35; rAd.CD40L

Latest Information Update: 06 Dec 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Memgen LLC
  • Developer Memgen; The Leukemia & Lymphoma Society; University of California, San Diego; University of Texas M. D. Anderson Cancer Center
  • Class Cancer vaccines; Gene therapies
  • Mechanism of Action CD40 ligand stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Malignant melanoma
  • No development reported Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 21 Nov 2017 Memgen withdraws a phase I/II trial prior to enrolment for Malignant melanoma (Combination therapy, Second-line therapy or greater, Late-stage disease, Metastatic disease) due to no IND serial number (Intratumoural) (NCT02719015)
  • 18 Nov 2015 Memgen has worldwide patent protection for ISF 35
  • 18 Nov 2015 Preclinical trials in Malignant melanoma (Refractory metastatic disease) in USA (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top